Marc Tessier-Lavigne Net Worth & Insider Trades

Marc Tessier-Lavigne - Director, Agios Pharmaceuticals Inc

As of June 23, 2016

What is Marc Tessier-Lavigne's Net Worth?

The current estimated net worth of Agios Pharmaceuticals Inc's Director, Marc Tessier-Lavigne, is estimated to be about $144.93M . Marc Tessier-Lavigne owns about 101,009 units of Agios Pharmaceuticals Inc common stock. In the last 3 years at Agios Pharmaceuticals Inc, Marc Tessier-Lavigne has sold an estimated value of $0 worth.

What is Marc Tessier-Lavigne's Past Insider Trading?

Marc Tessier-Lavigne's largest purchase order was 55,555 units , worth over $1M on April 3, 2014. In total, Marc Tessier-Lavigne has made about 5 transactions over 3 years of their time at Agios Pharmaceuticals Inc. Marc Tessier-Lavigne usually trades in June, with the busiest year in 2014.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Marc Tessier-Lavigne

Date Range: All Time
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...

InsideArbitrage

Our partner InsideArbitrage provides a full suite of tools and analysis that allows you to find opportunities from the hundreds of insiders transactions filed by company insiders each week. The service includes the popular Insider Weekends articles that highlight the top 5 insider purchases and sales each week as well as detailed analysis of one company each week. The service also includes several custom screens such as the Double Dipper that includes a list of companies that are buying back their shares while their insiders are independently buying stock on the open market for their own portfolios.

What is Marc Tessier-Lavigne's' Mailing Address?

  • Mailing address is 1 Dna Way South San Francisco CA 94080 CA

Agios Pharmaceuticals Inc Executive Compensation

Name
Year
Salary
Bonus
Stock Awards
Option Awards
Other Earnings Plans or Compensations
Other Compensation
Total
Jacqualyn A. Fouse, Ph.D. 2020 $746,750 - $1,751,340 $4,593,651 $509,657 $10,577 $7,611,975
Jacqualyn A. Fouse, Ph.D. 2019 $664,583 - $2,538,474 $12,875,608 $424,125 $105,204 $16,607,994
Jacqualyn A. Fouse, Ph.D. 2018 - - - - - - -
Jonathan Biller 2020 $500,000 - - - $258,750 $10,578 $769,328
Jonathan Biller 2019 $39,583 $110,000 $1,008,334 $2,025,036 - $936 $3,183,889
Jonathan Biller 2017 - - - - - - -
Christopher Bowden, M.D. 2020 $515,007 - $618,120 $1,508,875 $243,341 $9,203 $2,894,546
Christopher Bowden, M.D. 2019 $490,539 - $915,590 $1,609,989 $198,668 $12,422 $3,227,208
Christopher Bowden, M.D. 2018 $467,141 - $641,025 $1,746,517 $262,767 $11,280 $3,128,730
Bruce Car, Ph.D. 2020 $494,318 - $833,301 $1,499,943 $236,250 $164,231 $3,228,043
Bruce Car, Ph.D. 2019 - - - - - - -
Bruce Car, Ph.D. 2018 - - - - - - -
Andrew Hirsch 2020 $361,234 - $618,120 $1,508,875 - $397,893 $2,886,122
Andrew Hirsch 2019 $500,476 - $1,923,145 $1,609,989 $202,693 $12,528 $4,248,831
Andrew Hirsch 2018 $471,329 - $641,025 $1,746,517 $265,123 $12,864 $3,136,858
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1439222/000119312521110205/d71514ddef14a.htm

What are Agios Pharmaceuticals Inc's Past Insider Trades?

Agios Pharmaceuticals Inc's most recent insider trade came on September 28, 2023 by Cecilia Jones who sold 2,179 units worth $54.02K . In the last 10 years, insiders at Agios Pharmaceuticals Inc have sold an estimated value of $175.46M and bought an estimated value of $173.58M worth of shares. Insider trading is most common in June, with the busiest year in 2014. The most active traders at the company are David Schenkein, Director,  Scott Biller, Chief Scientific Officer,  and John Duncan Higgons, Chief Operating Officer .

AGIOS PHARMACEUTICALS, INC. Insider Trades

Date Range: All Time
Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...